We are live on ! Find out more
WINT

Windtree Therapeutics
WINT

Delisted

WINT was delisted on the 20th of August, 2025.

Back to rankings

5 hedge funds and large institutions have $57K invested in Windtree Therapeutics in 2025 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

5.97% more ownership

Funds ownership: 0.07% → 6.04% (+6%)

48% less capital invested

Capital invested by funds: $109K → $57K (-$51.7K)

55% less funds holding

Funds holding: 11 → 5 (-6)

86% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 7

Holders
5
Holders Change
-6
Holders Change %
-54.55%
% of All Funds
0.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
4
Reduced
–
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$170K
2
Morgan Stanley
Morgan Stanley
New York
+$92.5K
3
TRCT
Tower Research Capital (TRC)
New York
+$7.93K
4
Bank of America
Bank of America
North Carolina
+$610
5
SS
SBI Securities
Japan
+$142

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$41.7K
2
Geode Capital Management
Geode Capital Management
Massachusetts
-$20.7K
3
XT
XTX Topco
Cayman Islands
-$6.8K
4
Two Sigma Investments
Two Sigma Investments
New York
-$5.05K
5
CSS
Cubist Systematic Strategies
Connecticut
-$4.78K

WINT Hedge Fund Activity: Q1 2025 in Review

5 of the 7,472 institutional investors tracked by Wall St. Rank reported a position in Windtree Therapeutics (WINT) for Q1 2025, worth a combined $57K — down 48% from $109K a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of WINT and 1 opened new positions — a net loss of 6 holders — while 0 trimmed existing stakes and 4 added.

The largest buyer was UBS Group, adding an estimated $170K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $41.7K sold.

  • 5 institutional investors held Windtree Therapeutics (WINT) as of Q1 2025, down from 11 in Q4 2024.
  • Funds reported $57K of Windtree Therapeutics stock for Q1 2025, down 48% quarter-over-quarter.
  • 1 fund opened new Windtree Therapeutics positions in Q1 2025 and 7 closed out, a net change of -6 holders.
  • The largest Windtree Therapeutics buyer in Q1 2025 was UBS Group, an estimated $170K added.
  • The largest Windtree Therapeutics seller in Q1 2025 was Renaissance Technologies, an estimated $41.7K sold.

Based on aggregated 13F filings for Q1 2025.